Flow and endothelial signaling in acquired myxomatous valve disease
获得性粘液瘤性瓣膜疾病中的血流和内皮信号传导
基本信息
- 批准号:10033435
- 负责人:
- 金额:$ 72.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:ADAMTSAddressAdultAffectAgeBiologyBlood flowCanis familiarisCardiovascular DiseasesCardiovascular systemCell ProliferationCellsCellular biologyCleaved cellComplementDNA Sequence AlterationDepositionDevelopmentDiseaseEndothelial CellsEndotheliumEnvironmentEventGene ExpressionGeneticGenetic ModelsHeart ValvesHemorrhageHomeostasisHumanIncidenceIndividualInheritedMesenchymalMitral ValveMitral Valve ProlapseModelingMolecularMusPathogenesisPathologicPathologyPathway interactionsPeptide HydrolasesPopulationProductionProteoglycanProteolysisRoleSignal TransductionSyndromeTestingTetracyclinesdisease phenotypeenvironmental changeheart valve transplantationhemodynamicsinsightinterstitial cellmouse geneticsmouse modelmutantnovelparacrinepreventsingle-cell RNA sequencingtooltranscription factorversican
项目摘要
Project Summary
Myxomatous valve disease (MVD) arises in 2-3% of the human population and causes
mitral valve prolapse and regurgitation. Although rare inherited forms of MVD have been
identified, most cases arise in previously healthy valves in older individuals. MVD is
characterized by proliferation of valve interstitial cells (VICs), increased matrix
production, and TGFb signaling, but how such changes arise in previously healthy
valves is unknown. We have recently demonstrated that hemodynamic shear forces
direct heart valve development through expression of the flow-regulated KLF2 and KLF4
transcription factors in valve endothelial cells (VECs), but whether and how the
hemodynamic environment might regulate the function of the mature heart valve has not
been addressed. Our preliminary studies reveal that inducible genetic loss of KLF2 and
KLF4 in mature VECs results in a MVD phenotype associated with high VEC and VIC
proliferation, increased matrix deposition, and evidence of pathologic endothelial-
mesenchymal transition (EndMT). Importantly, we find that similar MVD pathology is
conferred by loss of blood flow across the mitral valve of transplanted hearts. These
findings support a novel mechanism for MVD in which changes in hemodynamic
conditions that alter VEC KLF2/4 expression give rise to acquired MVD. This proposal
will test this hemodynamic mechanism for MVD using new genetic tools to examine how
blood flow and KLF2/4 in VECs control the cellular biology (Aim 1) and the matrix biology
(Aim 2) of the mature valve. The proposed studies are expected to provide new insight
into MVD pathogenesis, the role of blood flow in adult heart valve homeostasis, and the
role of pathologic EndMT in the cardiovascular disease.
项目摘要
粘液瘤性瓣膜病(MVD)在2-3%的人群中出现,并引起
二尖瓣脱垂和反流。尽管罕见的遗传性MVD已经被
大多数病例发生在老年人先前健康的瓣膜中。MVD是
特征在于瓣膜间质细胞(VIC)增殖,基质增加,
生产,和TGF β信号,但这些变化如何出现在以前的健康
阀门未知。我们最近证明了血液动力学剪切力
通过表达流量调节的KLF 2和KLF 4指导心脏瓣膜发育
转录因子在瓣膜内皮细胞(VECs),但是否以及如何
血流动力学环境可能调节成熟心脏瓣膜的功能,
已经解决了。我们的初步研究表明,KLF 2和KLF 3基因的可诱导遗传丢失可能与KLF 2基因的表达有关。
成熟VEC中的KLF 4导致与高VEC和维克相关的MVD表型
增殖,基质沉积增加,以及病理性内皮-
间充质转化(EndMT)。重要的是,我们发现类似的MVD病理学是
这是由于移植心脏二尖瓣的血流损失造成的。这些
研究结果支持了MVD的新机制,其中血流动力学的变化
改变VEC KLF 2/4表达的条件引起获得性MVD。这项建议
将使用新的遗传工具测试MVD的血流动力学机制,以研究如何
血管内皮细胞中的血流和KLF 2/4控制细胞生物学(目的1)和基质生物学
(Aim 2)成熟的瓣膜。预计拟议的研究将提供新的见解
MVD的发病机制,血流在成人心脏瓣膜稳态中的作用,
病理性EndMT在心血管疾病中的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK L KAHN其他文献
MARK L KAHN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK L KAHN', 18)}}的其他基金
Genetic Investigation of Covid 19 in Lung Disease
Covid 19 在肺部疾病中的基因研究
- 批准号:
10673004 - 财政年份:2022
- 资助金额:
$ 72.58万 - 项目类别:
Reciprocal VEGFC/VEGFR3-CDH5 regulation of lymphatic and sinusoidal vascular growth
VEGFC/VEGFR3-CDH5 对淋巴管和窦状血管生长的相互调节
- 批准号:
10417684 - 财政年份:2022
- 资助金额:
$ 72.58万 - 项目类别:
Genetic Investigation of Covid 19 in Lung Disease
Covid 19 在肺部疾病中的基因研究
- 批准号:
10502908 - 财政年份:2022
- 资助金额:
$ 72.58万 - 项目类别:
Genetic Investigation of Covid 19 in Lung Disease
Covid 19 在肺部疾病中的基因研究
- 批准号:
10768221 - 财政年份:2022
- 资助金额:
$ 72.58万 - 项目类别:
Reciprocal VEGFC/VEGFR3-CDH5 regulation of lymphatic and sinusoidal vascular growth
VEGFC/VEGFR3-CDH5 对淋巴管和窦状血管生长的相互调节
- 批准号:
10608143 - 财政年份:2022
- 资助金额:
$ 72.58万 - 项目类别:
Molecular and genetic basis of deep venous thrombosis
深静脉血栓形成的分子和遗传学基础
- 批准号:
10460687 - 财政年份:2021
- 资助金额:
$ 72.58万 - 项目类别:
Flow and endothelial signaling in acquired myxomatous valve disease
获得性粘液瘤性瓣膜疾病中的血流和内皮信号传导
- 批准号:
10226236 - 财政年份:2020
- 资助金额:
$ 72.58万 - 项目类别:
Flow and endothelial signaling in acquired myxomatous valve disease
获得性粘液瘤性瓣膜疾病中的血流和内皮信号传导
- 批准号:
10626893 - 财政年份:2020
- 资助金额:
$ 72.58万 - 项目类别:
Flow and endothelial signaling in acquired myxomatous valve disease
获得性粘液瘤性瓣膜疾病中的血流和内皮信号传导
- 批准号:
10408810 - 财政年份:2020
- 资助金额:
$ 72.58万 - 项目类别:
MEKK3 signaling in hemogenic endothelium
造血内皮细胞中的 MEKK3 信号传导
- 批准号:
10198023 - 财政年份:2018
- 资助金额:
$ 72.58万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 72.58万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 72.58万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 72.58万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 72.58万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 72.58万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 72.58万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 72.58万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 72.58万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 72.58万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 72.58万 - 项目类别:
Research Grant














{{item.name}}会员




